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Acute fibrinous and organizing pneumonia (AFOP) has recently been identified as an unusual
variant of acute lung injury. We describe a man with rapidly progressive lung disease who
had AFOP detected via surgical lung biopsy. The patient acutely decompensated while in
the hospital and required mechanical ventilation as well as a prolonged ICU stay. He responded
poorly to initial treatment and progressively worsened, but he subsequently responded very
well to combined therapy with mycophenolate mofetil and methylprednisolone. The combina-
tion of corticosteroids and mycophenolate may provide a safe and effective treatment strategy
for severe forms of this newly defined pulmonary syndrome.
ª 2009 Elsevier Ltd. All rights reserved.Case description
A 56-year-old Caucasian male with a history of severe chronic
obstructive pulmonary disease (COPD) (FEV1Z 0.86; 21%of Cincinnati College of
cinnati, OH, USA. Fax: þ513
c.edu (S. Bhatti).
9 Elsevier Ltd. All rights reservedpredicted), nonocclusive coronary artery disease, and gastro
esophageal reflux disease was admitted to our hospital for
evaluation of six weeks history of progressive, non-productive
cough that was associated with dyspnea, chest pressure, and
new infiltrates on thoracic imaging. He was employed as
a forklift operator and was not aware of any occupational
exposures. Hewas a smoker (30 pack years) but quit smoking 2
weeks prior to presentation due to worsening respiratory
symptoms.Hehadbeenseen in thehospital 2weeksearlier for.
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coronary syndrome. A chest radiograph showed bilateral
reticulonodular opacifications with basal predominance
(Fig. 1A). A CT scan confirmed bilateral changes of consoli-
dation (Fig. 1B). The patient was given oral azithromycin for
presumed community-acquired pneumonia but had progres-
sive worsening of his symptoms and developed high grade
fevers with chills and night sweats and re-presented for
evaluation.
On admission the patient was alert with body tempera-
ture of 98 F (oral), pulse 95/min, respiratory rate 16/min
and blood pressure 155/87 mm Hg. He appeared lethargic
but had no obvious signs of respiratory discomfort. Cardiac
and abdominal exams were normal and there was no
peripheral edema. Chest auscultation revealed decreased
air entry and prolonged expiration without any wheezes or
rhonchi. Faint rales were heard over the mid lung fields
bilaterally, with diminished breath sounds at the apices and
bases.
Laboratory data revealed a white blood count of 16,900/
ml, hemoglobin 12 gm/dl, and platelet count of 451,000.
Erythrocyte sedimentation rate was mildly elevated at
53 mm/h. Electrolytes, creatinine, liver function tests and
urine analysis was normal. A sputum Gram smear showed
scant numbers of neutrophils, and sputum culture detected
growth of normal respiratory flora. Arterial blood gas at room
air revealed pH 7.43, PaO2 61 mm Hg and a PaCO2 39 mm Hg.
A repeat CT scan revealed progression of the ill-defined
pulmonary opacities (consolidation) located predominantly
in the mid and lower lung fields without any evidence ofFigure 1 Initial chest radiograph showing subtle infiltrate (A); in
(B); CT scan showing progression of bilateral infiltrates (C); chest rhilar or mediastinal adenopathy (Fig. 1C). The disease
seemed to spare the extreme periphery of the lung but
affected the lower lobe in a more proximal, peribronchial
location. No microorganisms were detected in BAL speci-
mens. Despite being started on broad spectrum intravenous
antibiotics (pipercillin-tazobactam, vancomycin and levo-
floxacin), fever persisted and dyspnea progressed.
Bronchoscopy performed on hospital day 2 did not reveal
any endobronchial lesions or abnormal secretions. Bron-
choalveolar lavage (BAL) and trans-bronchial biopsies were
performed in the right lower lobe (lateral and posterior
basilar segments). The patient developed a respiratory rate
of 40 per min after the procedure and was transferred to
the ICU for close monitoring. He subsequently required
intubation and continued to deteriorate clinically over the
next 4 days requiring a high FiO2 [FiO2 90%, PEEP 5 cm, H2O,
arterial blood PaO2 66 mm Hg] to maintain adequate
oxyhemoglobin saturation. Daily bedside chest radiographs
showed progression of the bilateral infiltrates.
The trans-bronchial biopsies revealed a non-specific
pattern of inflammation and no evidence of infection or
malignancy. A surgical lung biopsy was subsequently obtained
from the left lower lobe and left upper lobe to obtain
a definitive diagnosis. The pathology findings showed patchy
involvement of lung parenchymaby fibrin deposits in the form
of ‘‘fibrinballs’’ in alveolar ducts andalveoli (Fig. 2A andB). In
addition mild interstitial widening with mild inflammatory
infiltrate (including mononuclear cells and neutrophils) was
noted. Classical organizing pneumonia with intra-alveolar
fibroblastic plugs ‘‘Masson bodies’’ was also present as a lessitial chest CT scan showing bilateral reticulonodular infiltrate
adiograph showing bilateral infiltrates with consolidation (D).
Figure 2 A: 100 photomicrograph showing fibrin deposits in the form of ‘‘fibrin balls’’ in alveolar ducts and alveoli. B: 400
photomicrograph showing mild interstitial widening with mild inflammatory infiltrate including mononuclear cells and neutrophils.
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special stains for fungal and mycobacterial organisms were
negative. Findings were consistent with the reported
description of acute fibrinous and organizing pneumonia
(AFOP). The pathology specimenswere sent for verification to
the Armed Forces Institute of Pathology, Washington DC
[where the first 17 cases were reported], and the diagnosis of
AFOP was confirmed.
After establishing the diagnosis of AFOP, antibiotics were
discontinuedand thepatientwas startedonboth intravenous
methylprednisone at 1 mg/kg as well as mycophenolate
mofetil (MMF) 500 mgPO twice daily via his feeding tube. The
PaO2/FiO2 ratio gradually improved over the first few days of
therapywith a decrease in ventilator requirements (FiO2 40%
with PEEP 5 cm H2O; arterial blood gas with PaO2 69 mm Hg,
PCO256 mmHg,pH7.45). Subsequently however, thepatient
could not be weaned off the ventilator and chest radiograph
(Fig. 1D) did not show resolution or significant improvement
in the bilateral infiltrates. TheMMF dosewas increased to 1 g
twice daily one week later. The patient gradually improved,
and the clinical response was accompanied by resolution of
radiographic infiltrates over the subsequent 5 days as he was
weaned frommechanical ventilation on hospital day number
20. He was discharged on a tapering schedule of prednisone
while continuing mycophenolate as mycophenolate sodium
(myfortic) at 360 mg twice daily. After 12 months of follow-
up, the patient had regained 26 lbs and had greatly improved
exercise capacity.Comment
In 2002 Beasley et al.1 described a new histological pattern
of diffuse infiltrative lung disease that was termed acute
fibrinous and organizing pneumonia (AFOP). Tissue histo-
pathology revealed intra-alveolar fibrin in the form of fibrin
‘‘balls’’ and organizing pneumonia with a patchy distribu-
tion. This pattern is differentiated from diffuse alveolar
damage (DAD) by the absence of hyaline membranes while
the lack of eosinophils distinguishes it from eosinophilic
pneumonia (EP).2 The fibrin deposition that is characteristic
of AFOP is typically patchy, with an average of 50% airspace
involvement, as opposed to the more diffuse changestypically present with DAD. In AFOP alveolar walls adjacent
to areas of fibrin deposition demonstrate a variety of
changes that can include acute or chronic inflammatory cell
infiltration, interstitial widening, and type II pneumocyte
hyperplasia. However, areas of lung tissue without fibrin
deposits typically show only minimal histological changes.1
Because of its patchy distribution, the diagnosis of the
AFOP is difficult to make on bronchoscopic biopsy speci-
mens. A confident diagnosis of AFOP is unlikely to be made
without performing a surgical lung biopsy.1
The onset of dyspnea and non-productive cough of less
than 2 months duration were observed in all 17 patients
described by Beasley et al.1 and our patient had similar
symptoms of six weeks duration prior to presentation.
Beasley et al.1 described two distinct patterns of disease
progression and outcomes: fulminant illness with rapid
progression to death and a sub-acute course with recovery.1
All 5 of the patients who required mechanical ventilation
died. Our patient had fulminant illness requiring mechan-
ical ventilation but responded to immunosuppressive
therapy. Additionally, our patient’s HRCT scan demon-
strated bilateral patchy lower lobe infiltrates that are
consistent with what has been observed in previous reports
of this entity.1,2
AFOP has been linked to infection, connective tissues
disorders, and occupational and drug exposures. It also
occurs as an idiopathic entity, and our patient did not
appear to have an associated exposure or disorder other
than cigarette smoking.
Beasley et al.1 and Damas et al.2 have treated AFOP with
various agents including steroids, antibiotics, and cyclophos-
phamide with varying clinical responses. Our patient
appeared to have a fulminant form of illness with inability to
wean the patient off the ventilator. Because a combination of
cyclophosphamide and prednisone had been reported as
a successful treatment regimen,2 we considered mycophe-
nolate, an immunosuppressive agent approved for the
prevention of transplant rejection, as a second agent in
combination with corticosteroid therapy. Mycophenolate has
been used to treat lupus nephritis that is refractory to cyclo-
phosphamide as well as patients who cannot tolerate cyto-
toxic therapy with cyclophosphamide. Mycophenolate has
also been used in scleroderma-associated ILD3,4 in addition to
AFOP treatment with mycophenolate mofetil and corticosteroids 1767steroids4 and has been found to be safe, well tolerated and
effective in preserving lung function in connective tissue
disease-related ILD.5 The dose of MMF used in these studies
ranged from 1 to 2 gm/day with a duration of 12e24 months,
and treatment with MMF was associated with a good safety
profile.3e6We obtained a good clinical responsewith oral MMF
at a dose of 1 gm twice daily combined with IV methylpred-
nisolone at 1 mg/kg.
The patient remains on these medications as an outpa-
tient and we plan on gradually tapering these over a year or
two. The optimal duration of therapy is not known for
AFOP, previous studies have treated anywhere from 12 to
24 months.2 Despite the higher cost of mycophenolate
mofetil, as compared with intravenous cyclophosphamide,
there are additional costs associated with cyclophospha-
mide infusion, including reimbursement for the infusion
unit and the cost for antiemetic agents, mesna, and leu-
prolide. Thus, the actual cost of cyclophosphamide therapy
may surpass that of mycophenolate mofetil.6 The good
clinical response observed in our patient suggests that the
addition of mycophenolate to corticosteroids might be
a useful treatment for patients with AFOP.
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